Xeureka Leverages Confidential Computing and AI powered by Fortanix and NVIDIA to Transform the Pharmaceutical Development Process

Mitsui & Co. Subsidiary Improves the accuracy of AI models from 65% to 74% through collaboration on confidential data. It is expected to significantly reduce the time and cost associated with Drug Discovery

SANTA CLARA, Calif., , August 22, 2024

Fortanix® Inc., a leader in data-first cybersecurity and pioneer of Confidential Computing, today announced that Xeureka Inc., a subsidiary of Mitsui & Co. established to engage in early drug discovery research using a state-of-the-art technology, has successfully leveraged Fortanix and NVIDIA Confidential Computing technologies to significantly improve the accuracy of AI models, and is expected to reduce the time and costs associated with drug discovery.

Read full press release: https://www.fortanix.com/company/pr/2024/08/transform-the-pharmaceutical-development-process-through-confidential-computing-and-ai